Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hypertension
Volume 2013, Article ID 541689, 9 pages
http://dx.doi.org/10.1155/2013/541689
Clinical Study

Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study

1Clinical Cardiology Institute A.L. Myasnikov FSI Russian Cardiology Scientific and Production Complex Ministry of Health, 3rd Cherepkovskaya No. 15, Moscow 121552, Russia
2Neurovascular Hypertension and Kidney Disease Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, VIC 8008, Australia

Received 19 November 2012; Accepted 12 January 2013

Academic Editor: Eduardo Vera Tibiriçá

Copyright © 2013 Irina Chazova and Markus P. Schlaich. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [20 citations]

The following is the list of published articles that have cited the current article.

  • Eun-Ok Lee, and Kozyreva Olga, “Complex exercise rehabilitation program for women of the II period of age with metabolic syndrome,” Journal of Exercise Rehabilitation, vol. 9, no. 2, pp. 309–315, 2013. View at Publisher · View at Google Scholar
  • Christos V Rizos, and Moses S Elisaf, “Antihypertensive drugs and glucose metabolism.,” World journal of cardiology, vol. 6, no. 7, pp. 517–30, 2014. View at Publisher · View at Google Scholar
  • Elisabeth A. Lambert, Nora E. Straznicky, John B. Dixon, and Gavin W. Lambert, “Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity?,” American Journal Of Physiology-Heart And Circulatory Physiology, vol. 309, no. 2, pp. H244–H258, 2015. View at Publisher · View at Google Scholar
  • Alicia A. Thorp, and Markus P. Schlaich, “Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome,” Journal of Diabetes Research, vol. 2015, pp. 1–11, 2015. View at Publisher · View at Google Scholar
  • David Lang, Alexander Nahler, Thomas Lambert, Michael Grund, Jürgen Kammler, Jörg Kellermair, Hermann Blessberger, Alexander Kypta, Clemens Steinwender, and Johann Auer, “Anti-Inflammatory Effects and Prediction of Blood Pressure Response by Baseline Inflammatory State in Catheter-Based Renal Denervation,” The Journal of Clinical Hypertension, 2016. View at Publisher · View at Google Scholar
  • Francesca Cagnoni, Maurizio Destro, Erika Bontempelli, Giovanni Locatelli, Dagmara Hering, and Markus P. Schlaich, “Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?,” Current Hypertension Reports, vol. 18, no. 2, 2016. View at Publisher · View at Google Scholar
  • Nedogoda, “Combination of ace inhibitor with agonist of i1-imidazoline receptors: New opportunities for antihypertensive therapy,” Russian Journal of Cardiology, vol. 140, no. 12, pp. 103–108, 2016. View at Publisher · View at Google Scholar
  • Zykova, and Ostroumova, “Renoprotection with metabolic syndrome: The possibility of receptor agonist imidazoline moxonidine,” Kardiologiya, vol. 56, no. 10, pp. 72–79, 2016. View at Publisher · View at Google Scholar
  • Elisabeth A. Lambert, Carolina I. Sari, Nina Eikelis, Sarah E. Phillips, Mariee Grima, Nora E. Straznicky, John B. Dixon, Murray Esler, Markus P. Schlaich, Geoffrey A. Head, and Gavin W. Lambert, “Effects of Moxonidine and Low-Calorie Diet: Cardiometabolic Benefits from Combination of Both Therapies,” Obesity, 2017. View at Publisher · View at Google Scholar
  • Daniela Guarino, Monica Nannipieri, Giorgio Iervasi, Stefano Taddei, and Rosa Maria Bruno, “The Role of the Autonomic Nervous System in the Pathophysiology of Obesity,” Frontiers in Physiology, vol. 8, 2017. View at Publisher · View at Google Scholar
  • Wenfeng Zhang, Xuanfei Li, Yanmin Liu, Hao Chen, and Jianping Gong, “Activation of imidazoline I 1 receptor by moxonidine regulates the progression of liver fibrosis in the Nrf2-dependent pathway,” Biomedicine & Pharmacotherapy, vol. 90, pp. 821–834, 2017. View at Publisher · View at Google Scholar
  • Revathy Carnagarin, Cynthia Gregory, Omar Azzam, Graham S. Hillis, Carl Schultz, Gerald F. Watts, Damon Bell, Vance Matthews, and Markus P. Schlaich, “The Role of Sympatho-Inhibition in Combination Treatment of Obesity-Related Hypertension,” Current Hypertension Reports, vol. 19, no. 12, 2017. View at Publisher · View at Google Scholar
  • Revathy Carnagarin, Vance B. Matthews, Lakshini Y. Herat, Jan K. Ho, and Markus P. Schlaich, “Autonomic Regulation of Glucose Homeostasis: a Specific Role for Sympathetic Nervous System Activation,” Current Diabetes Reports, vol. 18, no. 11, 2018. View at Publisher · View at Google Scholar
  • Hamish C.G. Prosser, Omar Azzam, and Markus P. Schlaich, “Resistant Hypertension: Which Agent?,” Heart, Lung and Circulation, 2018. View at Publisher · View at Google Scholar
  • Revathy Carnagarin, Vance Matthews, Cynthia Gregory, and Markus P. Schlaich, “Pharmacotherapeutic strategies for treating hypertension in patients with obesity,” Expert Opinion on Pharmacotherapy, pp. 1–9, 2018. View at Publisher · View at Google Scholar
  • Jesper Futtrup, Merete Nordentoft, Betina Elfving, and Jesper Krogh, “The association between norepinephrine and metabolism in patients with major depression,” Neurology, Psychiatry and Brain Research, vol. 30, pp. 91–97, 2018. View at Publisher · View at Google Scholar
  • Shengli Dong, Matthias Blüher, Yanqing Zhang, Hongju Wu, and Suresh K. Alahari, “Development of insulin resistance in Nischarin mutant female mice,” International Journal of Obesity, 2018. View at Publisher · View at Google Scholar
  • Soulmaz Shorakae, Elisabeth A. Lambert, Eveline Jona, Carolina Ika Sari, Barbora de Courten, John B. Dixon, Gavin W. Lambert, and Helena J. Teede, “Effect of Central Sympathoinhibition With Moxonidine on Sympathetic Nervous Activity in Polycystic Ovary Syndrome—A Randomized Controlled Trial,” Frontiers in Physiology, vol. 9, 2018. View at Publisher · View at Google Scholar
  • Shepeleva, Rodionov, and Fomin, “Pharmacotherapy of resistant arterial hypertension,” Terapevticheskii Arkhiv, vol. 90, no. 4, pp. 4–7, 2018. View at Publisher · View at Google Scholar
  • G. V. Ramenskaya, I. E. Shokhin, N. I. Gaponova, and V. R. Abdrakhmanov, “Assessment of in Vitro Comparative Dissolution Kinetics of Moxonidine Products as a Factor Potentially Determining Effectiveness of Antihypertensive Treatment,” Rational Pharmacotherapy in Cardiology, vol. 14, no. 6, pp. 951–957, 2019. View at Publisher · View at Google Scholar